Drug news

Pernix Therapeutics acquires US rights to Treximet for Migraine from GSK

Read time: 1 mins

Last updated:15th May 2014

Published:15th May 2014

Source: Pharmawand

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, announced that it has signed an agreement with GlaxoSmithKline to acquire for $250 million, the U.S rights to Treximet (sumatriptan / naproxen sodium) for the acute treatment of Migraine attacks with or without aura in adults. Pernix�s team of approximately 90 specialty sales professionals will support the sales and marketing of Treximet in the US.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

FDA approves high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm) injection, interchangeable biosimilar to Humira

Boehringer Ingelheim announced that the FDA has approved the high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm), the company’s interchangeable* biosimilar to Humira (adalimumab), to treat multiple chronic inflammatory diseases

1 mins

Drug news

FDA approval for Inceptiv closed-loop spinal cord stimulator stimulator (SCS)for the treatment of chronic pain

Medtronic plc announced that the FDA has approved the Inceptiv closed-loop rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain

1 min

Drug news

The FDA has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia below-the-knee

Abbott announced that the FDA has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK)

2 min

See all news